Description
Elcar Pharmacodynamics
Elcar – a remedy for the correction of metabolic processes.
L-carnitine (natural substance related to B vitamins) is involved in metabolic processes as a carrier of fatty acids across cell membranes from the cytoplasm to the mitochondria where these acids are oxidized (beta-oxidation process) with the formation of large amounts of metabolic energy (in the form of ATP). L-carnitine increases resistance of nervous tissue to damaging factors (hypoxia, trauma, intoxication, etc.), inhibits ketoacid formation and anaerobic glycolysis, reduces the degree of lactacidosis. The drug replenishes blood alkaline reserve, restores autoregulation of cerebral hemodynamics and increases blood supply to the affected area, accelerates reparative processes in the lesion and has an anabolic effect.
Indications
Elcar is used as part of complex therapy in acute hypoxic conditions (acute cerebral hypoxia, ischemic stroke, transient ischemic attack). The drug is prescribed in acute, subacute and recovery periods of cerebral circulation disorders. It is used for discirculatory encephalopathy and various traumatic and toxic lesions of the brain, in the recovery period after surgical interventions. Elcar is indicated for primary and secondary carnitine deficiency, including in patients with chronic renal failure, those on hemodialysis, in cardiomyopathy, coronary heart disease (angina, acute myocardial infarction, postinfarction conditions), hypoperfusion due to cardiogenic shock and other myocardial metabolic disorders.
Contraindications
Individual intolerance, pregnancy, lactation (at present, there are no data on the possibility and safety of using the drug during pregnancy and lactation).
Dosage and administration
- One ampoule contains 0.5 g of the active substance.
- Elcar is administered intravenously, slowly or by trickle (2-3 min) or intravenously. Before intravenous administration, the ampoule contents are dissolved in 100-200 ml of solvent (0.9% sodium chloride solution or 5% dextrose (glucose) solution).
- In acute cerebral circulation disorders, 1 g/day (2 ampoules) is prescribed for 3 days, and then 0.5 g/day (1 ampoule) for 7 days. After 10-12 days, repeated courses of 3-5 days are possible.
- When prescribing the drug in subacute and recovery period, in discirculatory encephalopathy and different brain lesions, carnitine deficiency patients are given Elcar® solution at a rate of 0.5-1 g/day (1-2 ampoules) intravenously (drops, streaming) or v/m (2-3 times a day) without dilution for 3-7 days. If necessary, repeat course in 12-14 days.
- Intravenous injection, slowly (2-3 min) is administered in secondary carnitine deficiency during hemodialysis – 2 g (4 ampoules) once (after the procedure); during acute myocardial infarction, acute heart failure – 3-5 g/day (6-10 ampoules), divided into 2-3 receipts during the first 2-3 days with subsequent reduction of the dose by 2 times; during cardiogenic shock – 3-5 g/day (6-10 ampoules), divided into 2-3 receipts until the patient is out of shock. Then switch to oral administration of Elcar®.